NLS

While reports of federal cutbacks across the US health, life sciences, and research landscapes continue to fuel anxiety among scientists, the situation may not be as dire as people fear, according to one investor.

“To be able to control costs and serve patients, the world will need biosimilars,” says Róbert Wessman, Icelandic businessman and entrepreneur.

For Sirpa and Markku Jalkanen of Finland, M.D. and Ph.D., married, immunotherapy researchers, working together came as naturally as a courtship.

Cardiovascular diseases have a high mortality rate and although prevention is key, there are many companies, including Nordic ones, determined to develop better treatments.

Victor Ambros, Professor of Molecular Medicine and the Silverman Chair in Natural Sciences at the University of Massachusetts Chan Medical School, is one of this year’s winners of the Nobel Prize in Physiology or Medicine.

Four months after XNK Therapeutics, located in Huddinge, Sweden, declared bankruptcy, the clinical-stage biotechnology company’s building and physical assets were sold and the lease agreement transferred to BioLamina.